Evaluating the effect of metformine on antimullerian hormone(AMH ) in polycystic ovarian syndrome –a clinical trial

Evaluating the change of antimullerian hormone three month after metformine therapy in polycystic ovarian syndrome in comparison with control group(women that use placebo instead of metformine)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014081918858N1

Enrollment

Registered

2015-02-21

Start date

2014-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome.

Interventions

Intervention 1: Intervention group:Metformin, 500mg oral tablet, Three times a day for three months. Intervention 2: Control group: Placebo,oral tablet, Three times a day for three months.

Treatment - Drugs

Intervention group:Metformin, 500mg oral tablet, Three times a day for three months

Control group: Placebo,oral tablet, Three times a day for three months

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:1-age between 18-45 2- patienst without cardiovascular. renal and hepatic disease 3- patients must be new cases exclusion criteria: 1- use of oral anticoagulant drug during study 2-stop using metformine during study 3-pregnancy 4-body mass index below eighteen 5- sever hirsutism 6-amenorrhea7-use of clomiphene citrate or other ovulation induction drugs 8-cushing syndrome 9- using drugs that cause hirsutism 10- congenital adrenal hyperplasia 11- hypothyroidism 12- androgen producing ovarian tumors 13- prolactinoma 14- diabet

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Testesterone. Timepoint: before treatment and after three months. Method of measurement: Ng/Ml.;Hip to waist ratio. Timepoint: Before treatment and after three months. Method of measurement: Without any unit.;FSH. Timepoint: before treatment and after three months. Method of measurement: IU/L.;LH. Timepoint: before treatment and after three months. Method of measurement: IU/L.;Age. Timepoint: Before treatment. Method of measurement: Year.;Hirsutism score. Timepoint: Before treatment and after three months. Method of measurement: Freeman galway score.;Prolactin. Timepoint: before treatment and after three months. Method of measurement: Ng/Ml.;AMH. Timepoint: before treatment and after three months. Method of measurement: Mg.;BMI. Timepoint: before treatment and after treatment. Method of measurement: m²/kg.;Kind of treatment. Timepoint: Before treatment. Method of measurement: mg.;17(oh)progesterone. Timepoint: before treatment. Method of measurement: Ng.;Menstural disorder. Timepoint: Before treatment and after three months. Method of measurement: Cycles lessthan26 days and more than 30 days.	—

Measure

Time frame

Testesterone. Timepoint: before treatment and after three months. Method of measurement: Ng/Ml.;Hip to waist ratio. Timepoint: Before treatment and after three months. Method of measurement: Without any unit.;FSH. Timepoint: before treatment and after three months. Method of measurement: IU/L.;LH. Timepoint: before treatment and after three months. Method of measurement: IU/L.;Age. Timepoint: Before treatment. Method of measurement: Year.;Hirsutism score. Timepoint: Before treatment and after three months. Method of measurement: Freeman galway score.;Prolactin. Timepoint: before treatment and after three months. Method of measurement: Ng/Ml.;AMH. Timepoint: before treatment and after three months. Method of measurement: Mg.;BMI. Timepoint: before treatment and after treatment. Method of measurement: m²/kg.;Kind of treatment. Timepoint: Before treatment. Method of measurement: mg.;17(oh)progesterone. Timepoint: before treatment. Method of measurement: Ng.;Menstural disorder. Timepoint: Before treatment and after three months. Method of measurement: Cycles lessthan26 days and more than 30 days.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026